J&J withdraws EU application for Imbruvica as EMA cites potential ‘serious side effects’

Entrance to the building of the French headquarters of Johnson and Johnson

Jean-Luc Ichard

The European Medicines Agency (EMA) board said that Johnson & Johnson (NYSE: JNJ) withdrew its application seeking expanded approval of the blood cancer drug Imbruvica on December 13, 2022.

The J&J unit sought approval for Imbruvica, a product of J&J and AbbVie (ABBVOTCQX:RHHBYOTCQX:RHHBFBIB

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *